Please login to the form below

Not currently logged in

oral cholesterol inhibitor

This page shows the latest oral cholesterol inhibitor news and features for those working in and with pharma, biotech and healthcare.

Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’

Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’

Another trial of healthy volunteers showed a greater reduction, with LDL cholesterol cut by 90%. ... The 90% drop in LDL cholesterol was seen in all single-dose levels tested.

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Pharma deals in September 2015 Pharma deals in September 2015

    Dezima's TA-8995 (phase 2b-complete), is an oral cholesterol ester transfer protein (CETP) inhibitor that has demonstrated dramatic LDL-C lowering, reducing levels of LDL-C by up to ... Collaboration - licence. 1, 700. Dezima. Amgen. TA-8995 an oral CETP

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts


Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

Healing the Healers
Because if we do not heal the healers, who is going to heal us?...
The (inevitable) digital transformation of Medical Affairs
It’s not a question of ‘if,’ it’s a question of ‘when.’...
Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment
Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...